09th week of 2018 patent applcation highlights part 27 |
Patent application number | Title | Published |
20180057560 | COMBINED T CELL RECEPTOR GENE THERAPY OF CANCER AGAINST MHC I AND MHC II-RESTRICTED EPITOPES OF THE TUMOR ANTIGEN NY-ESO-1 - The present invention relates to the field of immunotherapy, in particular adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer. The invention provides a nucleic acid encoding at least one T cell receptor alpha chain construct and/or TCR beta chain construct of a TCR construct capable of specifically binding to an epitope from NY-ESO-1 (also designated CTAG-1) in complex with a human MHC, wherein the TCR alpha chain construct and/or the TCR beta chain construct comprises a complementarity determining region 3 (CDR3) having at least 90% sequence identity to an amino acid selected from SEQ ID NO: 1-20. The invention provides TCR constructs restricted to an epitope from NY-ESO-1 presented on MHC I, and, for the first time, TCR constructs restricted to an epitope from NY-ESO-1 presented on MHC II molecules, and thus enables a combined adoptive T cell therapy with both recombinant CD4+ and re-combinant CD8+ T cells. The invention also provides proteins and host cells corresponding to said TCR constructs, as well as the medical use of such constructs, in particular, in the diagnosis, prevention, and/or treatment of a proliferative or viral disease, wherein, preferably, both TCR constructs restricted to MHC I and MHC II molecules are provided in a kit. The invention also relates to a mouse transgenic for the human TCR loci and human HLA-DR4, ABabDR4 mouse. | 2018-03-01 |
20180057561 | PD-L1 AND PD-L2-BASED FUSION PROTEINS AND USES THEREOF - Provided are fusion proteins comprising a first domain and a second domain, wherein the first domain comprises a polypeptide that binds to and triggers PD-1 and the second domain comprises a polypeptide that binds to and triggers a TRAIL receptor or Fas. In some embodiments, the polypeptide that binds to and triggers PD-1 comprises at least a portion of the extracellular domain of PD-L1 or PD-L2 and the second domain comprises at least a portion of the extracellular domain of TRAIL or Fas ligand. Also provided are methods for treating autoimmune, alloimmune or inflammatory diseases, and methods for treating cancer, using the fusion proteins. | 2018-03-01 |
20180057562 | UNIVERSAL ANTIBODY-MEDIATED BIOSENSOR - A universal antibody-mediated biosensor is provided that comprise a biosensor cell line stably expressing a novel chimeric fusion protein that can be used to detect target agents in a sample. The fusion protein has an extracellular antibody-binding domain that binds antibodies without regard to their binding specificity and a signaling domain that induces cellular activation upon antigen binding. Because the fusion protein binds to the Fc region of any antibody, it can serve as a universal pathway between extracellular signaling and intracellular activation. The biosensor can be used to detect the presence of selected antigens in a sample. | 2018-03-01 |
20180057563 | METHODS FOR EXPANDING IMMUNE CELLS - The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use. | 2018-03-01 |
20180057564 | ANTAGONISTS OF IL-20 FAMILY OF CYTOKINES AND THEIR USE - Methods for blocking the activity of the IL-20 family of cytokines in a mammal having a disorder-mediated by one or more of the IL-20 family of cytokines consisting of IL-19, IL-20 and IL-24 are disclosed. The methods involve administering a therapeutically effective amount of either a soluble IL-20R2-IgG Fc fusion protein or a neutralizing monoclonal antibody to IL-20R2, both of which are able to block the biological functions of all three members of IL-20 family of cytokines. | 2018-03-01 |
20180057565 | STABILIZED POLYPEPTIDE INSULIN RECEPTOR MODULATORS - Provided herein are stapled or stitched polypeptides comprising an alpha-helical segment, wherein the polypeptide binds to the insulin receptor, and wherein the peptide comprises at least two cross-linked amino acids as shown in Formula (iii), or at least three cross-linked amino acids as shown in Formula (iv). Further provided are pharmaceutical compositions comprising the stapled or stitched polypeptides, methods of use, e.g., methods of treating a diabetic condition or complications thereof. Precursor “unstapled” polypeptides useful in the preparation of stapled and stitched polypeptides are also described. | 2018-03-01 |
20180057566 | O-Linked Glycoforms Of Polypeptides And Method To Manufacture Them - The present invention relates to compositions comprising glycoproteins having altered patterns of O-linked glycosylation, in particular Factor VII, Factor IX, and methods for making these. | 2018-03-01 |
20180057567 | Multispecific Antibodies Facilitating Selective Light Chain Pairing - Provided herein are multispecific antibodies, e.g. bispecific antibodies, which are modified such that the desired chain pairing takes place and/or can be selected for. Specifically, this is achieved by using different dimerization domains for light chain pairing. Also disclosed herein are nucleic acids encoding for these antibodies, expression vectors comprising these nucleic acids, cells expressing them, and further to pharmaceutical compositions comprising the antibodies, as well as methods of isolating the antibodies. | 2018-03-01 |
20180057568 | REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE - The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content. | 2018-03-01 |
20180057569 | THERAPEUTIC USE OF SPECIFIC LIGAND IN MSRV ASSOCIATED DISEASES - A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6. | 2018-03-01 |
20180057570 | BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODY - The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided. | 2018-03-01 |
20180057571 | METHODS OF TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS AND ASSOCIATED CONDITIONS - The present invention relates to methods and compositions for preventing and treating | 2018-03-01 |
20180057572 | ANTIBODY BINDING A LINEAR EPITOPE OF HUMAN P53 AND DIAGNOSTIC APPLICATIONS THEREOF - The invention relates to an anti-human p53 antibody suitable for specifically binding a linear epitope which is exposed only in a conformationally altered isoform of the characteristic p53 protein of patients with Alzheimer's disease or prone to develop Alzheimer's disease or cognitive impairment during ageing. Methods and diagnostic and prognostic kits are also described. | 2018-03-01 |
20180057573 | MZB1, A NOVEL B CELL FACTOR, AND USES THEREOF - The marginal zone (MZ) and B1 subsets of B cells, which differ from conventional follicular (FO) B cells both developmentally and functionally, are involved in early responses to infectious pathogens and the production of self-reactive antibodies. A novel gene, mzb1, is expressed at high levels in MZ and B1 B cells but at low level, if at all, in FO B cells. MZB1 is involved in the regulation of proliferation, BCR-mediated signal transduction, and antibody production in B cells. Inhibitors, activators and enhancers of MZB1 expression or activity can be used as immune modulators for research and therapeutic purposes. | 2018-03-01 |
20180057574 | ANTI-HISTONE THERAPY IN ACUTE KIDNEY INJURY - Acute kidney injury (AKI) is often associated with damage to remote organs, such as lungs or heart. AKI induces kidney tubular necrosis as well as NETosis, programmed neutrophil death leading to neutrophil extracellular traps (NETs). Histones released during NETosis induces further formation of NETs, which is damaging to renal tissues and remote organs. Circulating trap-forming neutrophils directly injured the lung, while other dead tissue releases contributed to injury in other organs. Suppressing renal necroinflammation using inhibitors of NET formation, tubular cell necrosis or extracellular histones prevented kidney as well as remote organ injuries. Dual inhibition of neutrophil trap formation together with tubular cell necrosis had an additive protective effect. Preferably, damage to remote organs induced by AKI may be treated and/or prevented using anti-histone agents such as anti-histone IgG, recombinant activated protein C, or heparin, alone or in combination with other therapeutic agents, such as PAD inhibitors. | 2018-03-01 |
20180057575 | COMPOSITIONS AND METHODS OF USE FOR DETERMINATION OF HE4a - The invention includes the use of the HE/HE4a markers to assess ovarian cancer in a subject. Included also are compositions and methods of using HE/HE4a marker for diagnosis, grading and staging of ovarian cancers, determining prognosis and treatment effectiveness of a subject who has been diagnosed with ovarian cancer. | 2018-03-01 |
20180057576 | COMPLEMENT FACTOR Bb ANTIBODIES - The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement Factor Bb. Specifically, the disclosure is related to anti-complement Factor Bb antibodies. | 2018-03-01 |
20180057577 | Split Inteins, Conjugates and Uses Thereof - Disclosed herein are split inteins, fused proteins of split inteins, and methods of using split inteins to efficiently purify and modify proteins of interest. | 2018-03-01 |
20180057578 | Antibodies Specific for TGF-Beta - The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFβ), including TGFβ1, TGFβ2 and TGFβ3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFβ expression. | 2018-03-01 |
20180057579 | ANTAGONIST ANTIBODIES AGAINST GDF-8 AND USES THEREFOR - The disclosure provides improved neutralizing anti-GDF-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-GDF-8 antibodies. Also provided are methods of using compositions comprising such antibodies to increase muscle mass or strength, and to treat or prevent muscular disorders, neuromuscular disorders, metabolic disorders, adipose tissue disorders or bone disorders. | 2018-03-01 |
20180057580 | ANTI-GREMLIN-1 (GREM1) ANTIBODIES AND METHODS OF USE THEREOF FOR TREATING PULMONARY ARTERIAL HYPERTENSION - The present invention provides anti-Gremlin-1 (GREM1) antibodies, and antigen-binding fragments thereof, as well as methods of use of such antibodies, or antigen-binding fragments thereof, for treating a subject having pulmonary arterial hypertension (PAH). | 2018-03-01 |
20180057581 | ANTIBODIES TARGETING M-CSF - This disclosure generally relates to antibodies or antibody fragments which specifically bind to M-CSF. In particular antibodies and antibody fragments are disclosed which bind to M-CSF and which inhibit binding of M-CSF to the M-CSF receptor with an IC50 of 10 pM or less. The invention also relates to nucleic acids, vectors and host cells capable of expressing the antibodies or fragments thereof of the invention, pharmaceutical compositions comprising the antibodies or fragments thereof and uses of said antibodies or fragments thereof and compositions for treatment of specific diseases. | 2018-03-01 |
20180057582 | METHODS OF TREATMENT OF EOSINOPHILIC BRONCHITIS WITH AN ANTI-IL-5 ANTIBODY - The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, the present invention relates generally to the treatment of eosinophilic bronchitis with an anti-IL-5 antibody or fragment thereof. | 2018-03-01 |
20180057583 | ANTI-IL-25 ANTIBODIES AND USES THEREOF - The present invention provides antibodies that bind to human interleukin-25 (IL-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human IL-25 with high affinity. In certain embodiments, the invention includes antibodies that bind human IL-25 and block IL-25-mediated cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies. The antibodies of the invention are useful for the treatment of various disorders associated with IL-25 activity or expression, including asthma, allergy, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, atopic dermatitis (AD), and Eosinophilic Granulomatosis with Polyangiitis (EGPA), also know as Churg-Strauss Syndrome. | 2018-03-01 |
20180057584 | IL-17 ANTIBODY FORMULATION - The present invention provides pharmaceutical formulations for anti-IL-17 antibodies. These anti-IL-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing psoriatic arthritis or multiple myeloma. | 2018-03-01 |
20180057585 | TREATING VASCULAR DISEASE AND COMPLICATIONS THEREOF - Administration of an antibody that specifically binds IL-1α is useful for reducing the chance or severity of a major adverse clinical event occurring in a mammalian subject having received or expected to receive surgical treatment for a stenosed blood vessel, and for reducing the change of restenosis occurring (or increasing the time until restenosis occurs) in a mammalian subject having received or expected to receive surgical treatment for a stenosed blood vessel. | 2018-03-01 |
20180057586 | ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF - The present application relates to antibodies that specifically bind to hepcidin and methods of using the antibodies. Another aspect relates to antibodies which bind hepcidin and regulate iron homeostasis. Another aspect relates to the use of humanized antibodies which bind hepcidin for the treatment of a disease or condition associated with hepcidin. | 2018-03-01 |
20180057587 | ANTI-CLAUDIN 1 MONOCLONAL ANTIBODIES FOR THE PREVENTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA - Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given. | 2018-03-01 |
20180057588 | Antibodies Towards an Extracellular Region of NBCn1 - The present application discloses antibodies or antigen binding fragment thereof specifically recognizing and binding an extracellular polypeptide region of human NBCn1. Experimental data are detailed for mouse NBCn1 antibodies. The medical use of such antibodies is claimed, in particular for the treatment of hyperproliferative disorders, such as cancer, or atherosclerosis and/or restenosis. | 2018-03-01 |
20180057589 | ANTI-NOTCH2 NRR ANTIBODIES - The invention provides anti-Notch antibodies, and in particular, antibodies that bind Notch2 NRR, and methods of using the same. | 2018-03-01 |
20180057590 | DICAM-SPECIFIC ANTIBODIES AND USES THEREOF - Novel antibodies directed against Dual Ig domain containing cell adhesion molecule (DICAM) are described. These anti-DICAM antibodies are capable of detecting DICAM by Western blot and/or flow cytometry, blocking the interaction between DICAM and its ligand αVβ3 integrin, and/or blocking the migration of inflammatory cytokine-secreting T | 2018-03-01 |
20180057591 | ANTI-TIM-3 ANTIBODIES - The present invention relates to antibodies that bind human T-cell immunoglobulin- and mucin-domain-containing protein-3 (Tim-3), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation. | 2018-03-01 |
20180057592 | THERAPEUTIC CD47 ANTIBODIES - Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to CD47 of multiple mammalian species, block the binding of SIRPalpha and TSP1 to CD47, promote phagocytosis of susceptible cancer cells, and reverse TSP1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents for treating susceptible cancer cells, promoting their phagocytic uptake and clearance. | 2018-03-01 |
20180057593 | MASKED ANTI-CD3 ANTIBODIES AND METHODS OF USE - The invention provides masked anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same. | 2018-03-01 |
20180057594 | PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES - Described herein are pseudotyped oncolytic viruses comprising nucleic acids encoding an engager molecule. In some embodiments, the pseudotyped oncolytic viruses comprises nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the pseudotyped oncolytic virus and methods of treating cancer using the pseudotyped oncolytic viruses are further provided herein. | 2018-03-01 |
20180057595 | Anti-MET Antibodies and Methods of Use Thereof - Provided herein are compositions, methods and uses involving antibodies that specifically bind to MET, a receptor tyrosine kinase, and modulate the expression and/or activity of MET. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer. In one aspect, provided herein is a monoclonal antibody or antigen-binding fragment thereof that binds to the Sema/PSI domain of human MET. Also provided herein is a kit comprising an antibody or antigen-binding fragment provided herein. Also provided herein is a method of managing, protecting against, or treating cancer in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment provided herein. | 2018-03-01 |
20180057596 | BINDING MEMBERS OF INTERLEUKIN-4 RECEPTOR ALPHA (IL4-Ra) - Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4Rα), and their therapeutic use e.g., in treating or preventing disorders associated with IL-4Rα, IL-4 and/or IL-13, examples of which are asthma and COPD. | 2018-03-01 |
20180057597 | ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 - The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool. | 2018-03-01 |
20180057598 | MULTIVALENT AND MULTIEPITOPIC ANTIBODIES HAVING AGONISTIC ACTIVITY AND METHODS OF USE - Provided herein are tetravalent antigen binding complexes having agonist activity for a cell surface receptor. In some embodiments, the complexes comprise binding specificities for multiple epitopes of the same cell surface receptor. Further provided herein are nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production related thereto. | 2018-03-01 |
20180057599 | Fn14 Binding Proteins and Uses Thereof - The present disclosure provides proteins comprising antibody antigen binding domains that bind to Fn14 and uses thereof. The present disclosure also provides methods for treating wasting disorders, such as cachexia. | 2018-03-01 |
20180057600 | BINDING MOLECULES TO THE HUMAN OX40 RECEPTOR - The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions. | 2018-03-01 |
20180057601 | NOVEL HUMANIZED ADAM17 ANTIBODY - The present disclosure relates to a novel humanized antibody capable of binding to ADAM17 and also the amino and nucleic acid sequences coding for said antibody. From one aspect, the disclosure relates to a novel humanized antibody, or antigen-binding fragments, capable of binding to ADAM17 with anti-tumour activities. The disclosure also comprises the use of said humanized antibody as a drug for the treatment of cancer. Finally, the invention comprises compositions comprising said humanized antibody, alone or in combination or conjugation with other anticancer compounds, and the use of same for the treatment of cancer. | 2018-03-01 |
20180057602 | COMBINATION THERAPY OF CANCER WITH ANTI-ENDOGLIN ANTIBODIES AND ANTI-VEGF AGENTS - The present application relates to compositions of chimeric anti-endoglin antibodies and anti-VEGF agents. Another aspect relates to the use of chimeric anti-endoglin antibodies and Bevacizumab. Another aspect relates to the use of the compositions to inhibit VEGF induced sprouting. Another aspect relates to the use of the compositions to inhibit angiogenesis. | 2018-03-01 |
20180057603 | Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers - The present invention provides a fusion proteins comprising
| 2018-03-01 |
20180057604 | ANTI-TRANSFERRIN RECEPTOR / ANTI-BACE1 MULTISPECIFIC ANTIBODIES AND METHODS OF USE - The present invention relates to bispecific antibodies that bind to transferrin receptor and BACE1 and methods of using the same. | 2018-03-01 |
20180057605 | BLOOD BRAIN BARRIER TRANSPORT MOLECULES AND USES THEREOF - The disclosure provides transporter molecules capable of carrying agents of interest across the blood brain barrier. Also provided are polynucleotides encoding transporter molecules, methods making transporter molecules, and methods of using transporter molecules, e.g., for the diagnosis, prevention, or treatment of central nervous system diseases, disorders, or injuries. | 2018-03-01 |
20180057606 | METHODS OF TREATING MENINGIOMA - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 2018-03-01 |
20180057607 | METHOD FOR PRODUCING POLYPEPTIDE HETERO-OLIGOMER - It is intended to provide a method for efficiently and stably producing a heteromultimer by incubating homo variants of plural types of heavy chain constant region-containing polypeptides differing in antigen-binding activity under a reducing condition that reorganize the inter-polypeptide disulfide bond between cysteine residues outside of core hinge regions. A feature of the production method of the present invention is that amino acid residues in the core hinge regions do not form any disulfide bond. | 2018-03-01 |
20180057608 | BISPECIFIC ANTIBODY MOLECULE - The present invention relates to a method of treating a disease. The method comprises administering to a patient in need thereof a recombinant bispecific antibody molecule consisting of a Fab fragment comprising a first binding site for a first antigen, a single chain Fv fragment comprising a second binding site for a second antigen and an immunoglobulin IgG1 CH2 domain. The invention also relates to a nucleic acid molecule encoding a recombinant bispecific antibody molecule and to a host cell comprising the nucleic acid molecule | 2018-03-01 |
20180057609 | Enhancing Activity of CAR T Cells by Co-Introducing a Bispecific Antibody - The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof. | 2018-03-01 |
20180057610 | Therapeutic Use of Mitochondria and Combined Mitochondrial Agent - The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions. | 2018-03-01 |
20180057611 | READILY ISOLATED BISPECIFIC ANTIBODIES WITH NATIVE IMMUNOGLOBULIN FORMAT - The invention relates to antigen-binding proteins or antibodies having heterodimers of heavy chains, i.e., two immunoglobulin heavy chains that differ by at least one or two amino acid(s) that allows for isolation of the antigen-binding protein based on a differential affinity of an immunoglobulin heavy chain and a modified/mutated immunoglobulin heavy chain toward an affinity reagent. The invention also relates antigen-binding proteins, including bispecific antibodies, having IgG CH1 regions with different affinities with respect to affinity reagent(s) that allows rapid isolation by differential binding of the IgG regions to the affinity reagent(s). | 2018-03-01 |
20180057612 | HYPROMELLOSE ACETATE SUCCINATE AND METHOD FOR PRODUCING HYPROMELLOSE ACETATE SUCCINATE - Provided is a method for producing HPMCAS capable of reducing the average particle size of HPMCAS particles to an intended range without a pulverization step. Specifically provided is a method for producing hypromellose acetate succinate, comprising an esterification step of reacting hypromellose with an esterification agent in the presence of a catalyst to obtain a reaction solution containing crude hypromellose acetate succinate, a precipitation step of mixing the reaction solution with water to precipitate the crude hypromellose acetate succinate, thereby obtaining a hypromellose acetate succinate suspension, a liquid removal step of removing a liquid from the hypromellose acetate succinate suspension with a centrifugal decanter to obtain liquid-removed hypromellose acetate succinate, and a drying step of drying the liquid-removed hypromellose acetate succinate. | 2018-03-01 |
20180057613 | HYPROMELLOSE PHTHALATE AND METHOD FOR PRODUCING HYPROMELLOSE PHTHALATE - Provided is a method for producing HPMCP capable of reducing the average particle size of HPMCP particles to an intended range without a pulverization step. Specifically provided is a method for producing hypromellose phthalate, comprising an esterification step of reacting hypromellose with an esterification agent in the presence of a catalyst to obtain a reaction solution containing crude hypromellose phthalate, a precipitation step of mixing the reaction solution with water to precipitate the crude hypromellose phthalate, thereby obtaining a hypromellose phthalate suspension, a liquid removal step of removing a liquid from the hypromellose phthalate suspension with a centrifugal decanter to obtain liquid-removed hypromellose phthalate, and a drying step of drying the liquid-removed hypromellose phthalate. | 2018-03-01 |
20180057614 | DEPOLYMERISATION OF ALGINIC ACID - Depolymerisation of alginic acid by microwave treatment. | 2018-03-01 |
20180057615 | METHOD TO PREPARE RUBBER COMPOUNDS CONTAINING SILICON DIOXIDE FOR THE PRODUCTION OF TYRES - A rubber compound containing silicon dioxide for the production of tyres and comprising a polymer base with a cross-linkable unsaturated chain, a filler comprising silicon dioxide, a silane bonding agent and a vulcanization system. The filler further comprises a composite mineral consisting of a mineral of the zeolite family, onto which a layer of silicon dioxide has been deposited. | 2018-03-01 |
20180057616 | REDUCING RESIDUAL MONOMER CONTENT IN COPOLYMERS OF STYRENE AND VINYLPYRIDINE - Copolymers of styrene and vinylpyridine having residual monomer levels of less than about 1000 parts per billion and processes for preparing said copolymers. | 2018-03-01 |
20180057617 | Polymers with Functional Imide Groups and Pigment Dispersions and Coatings Formed Therefrom - A polymer having N-functional imide groups is prepared from reactants that include: (a) an ethylenically unsaturated anhydride or diacid monomer; (b) at least one co-monomer that is different from (a) having an ethylenically unsaturated group that is reactive with (a); and at least one compound reactive with the anhydride or diacid functional groups of (a) that is represented by Chemical Formula I: H | 2018-03-01 |
20180057618 | Novel Medium Density Polyethylene Compositions - An ethylene alpha-olefin copolymer having (a) a density of from about 0.910 g/cc to about 0.940 g/cc; (b) a weight average molecular weight of from about 150,000 g/mol to about 300,000 g/mol; and (c) a melt index at a load of 2.16 kg of from about 0.01 dg/10 min. to about 0.5 dg/min.; wherein a 1 mil blown film formed from the polymer composition is characterized by (i) a Dart Impact strength greater than about 175 g/mil; (ii) an Elmendorf machine direction tear strength greater than about 20 g/mil; and (iii) an Elmendorf transverse direction tear strength greater than about 475 g/mil. | 2018-03-01 |
20180057619 | SYSTEMS AND PROCESSES FOR POLYACRYLIC ACID PRODUCTION - Disclosed are systems and methods for the production of polyacrylic acid and superabsorbent polymers from ethylene oxidation to form ethylene oxide. Reacting the ethylene oxide with carbon monoxide to form to beta propiolactone (BPL) or polypropiolactone (PPL), or a combination thereof. An outlet configured to provide a carbonylation stream comprising the BPL or PPL, or a combination thereof and using one or more reactors to convert BPL to acrylic acid or to convert at least some of the BPL to PPL, and then to convert PPL to acrylic acid. An outlet configured to provide a PPL stream to a second reactor tm to convert at least some of the PPL to AA or a third reactor to convert at least some of the PPL to AA. The outlet configured to provide an AA stream to a fourth reactor to convert the AA to polyacrylic acid. | 2018-03-01 |
20180057620 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS - A solid catalyst component for the polymerization of olefins made from or containing Mg, Ti, halogen and an electron donor of formula (I) or (II) | 2018-03-01 |
20180057621 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS - A solid catalyst component for the polymerization of olefins made from or containing Mg, Ti, halogen and an electron donor of formula (I) or (II): | 2018-03-01 |
20180057622 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS - The present disclosure relates to a catalyst component for the polymerization of olefins comprising Mg. Ti and an electron donor such as mercaptoester derivatives of the general formula (I). | 2018-03-01 |
20180057623 | PROCESS FOR FORMING POLYOLEFINS - Processes of forming polyolefins are described herein. One or more specific embodiments of the processes generally include introducing olefin monomer selected from C | 2018-03-01 |
20180057624 | AMORPHOUS PROPYLENE-ETHYLENE COPOLYMERS - A low molecular weight copolymer is provided comprising propylene and ethylene,
| 2018-03-01 |
20180057625 | TETRAFLUOROETHYLENE AND PERFLUORINATED ALLYL ETHER COPOLYMERS - A copolymer having tetrafluoroethylene units and units independently represented by formula (I) in a range from 0.02 to 2 mole percent, based on the total amount of the copolymer. Rf is a linear or branched perfluoroalkyl group having from 1 to 8 carbon atoms and optionally interrupted by one or more —0— groups, n is independently from 1 to 6, and z is 0, 1, or 2. The copolymer has a melt flow index in a range from 20 grams per 10 minutes to 40 grams per 10 minutes. The copolymer can be extruded to make articles, such as insulated cables. A method of making the copolymer is also disclosed. | 2018-03-01 |
20180057626 | COPOLYMER - Provided is a novel copolymer that can express an excellent calcium ion-trapping ability. The copolymer of the present invention includes: 0.1 mol % to 99 mol % of a structural unit (A) derived from a monoethylenically unsaturated monocarboxylic acid (salt) monomer (a); 0.1 mol % to 99 mol % of a structural unit (B) derived from a monomer (b) serving as a monoethylenically unsaturated dicarboxylic acid (salt) or an anhydride thereof; and 0.1 mol % to 50 mol % of a structural unit (C) derived from an ether bond-containing hydrophobic monomer (c). | 2018-03-01 |
20180057627 | POLYMER, POLYMER DISPERSION, AND AQUEOUS INK - A polymer includes 2-carboxyethyl (meth)acrylate and alkyl (meth)acrylate as constituent units and having an acid value of 7 mg KOH/g to 100 mg KOH/g. | 2018-03-01 |
20180057628 | NITRILE RUBBER COMPOSITION AND CROSS-LINKED RUBBER - A nitrile rubber composition comprising a carboxyl group-containing highly saturated nitrile rubber containing α,β-ethylenically unsaturated nitrile monomer units in a ratio of 5 to 60 wt % and having an iodine value of 120 or less, carbon black, and a polyamine-based cross-linking agent, wherein a content of the carbon black is 100 parts by weight or more and less than 200 parts by weight with respect to 100 parts by weight of the carboxyl group-containing highly saturated nitrile rubber. Accordingly a nitrile rubber composition able to give a cross-linked rubber with excellent in original state physical properties, compression set resistance, and sour gasoline resistance and small in tension set is provided. | 2018-03-01 |
20180057629 | SUBSTRATE INCLUDING A SURFACE COATED WITH AN EPILAME AGENT AND METHOD FOR COATING SUCH A SUBSTRATE WITH EPILAME - The invention relates to a copolymer and a substrate having a surface, at least one part of which is coated with an epilame agent comprising at least one compound in the form of a copolymer comprising V units, N units, optionally at least one M unit, and optionally at least one P unit, linked by covalent bonds by their main chains, wherein | 2018-03-01 |
20180057630 | POLYURETHANE FILTER FOAM - A polyurethane filter foam is provided herein. The polyurethane filter foam may have improved permeability by having both a small cell and a large cell in a range for maximizing the opening property of the foam. In some instance, this is achieved by specifically configuring and foaming a composition of polyether polyol and methylene diphenyl diisocyanate (MDI) to manufacture the polyurethane foam. The polyurethane foam of the present invention can be manufactured without performing a reticulation process. | 2018-03-01 |
20180057631 | ZINC SULFIDE COUPLING AGENTS - An article of manufacture includes a zinc sulfide layer and a coupling agent adhered to the zinc sulfide layer by a disulfide bond. The coupling agent comprises a functional group extending from the zinc sulfide layer. | 2018-03-01 |
20180057632 | CONDUCTIVE COMPOSITION FOR FORMING SOLAR CELL COLLECTOR ELECTRODE, SOLAR CELL, AND SOLAR CELL MODULE - An object of the present invention is to provide: a conductive composition for forming a solar cell collector electrode that can form a collector electrode with favorable adhesion with regard to a transparent conductive layer; a solar cell having a collector electrode formed using the composition; and a solar cell module. A conductive composition for forming a solar cell collector electrode, includes: a metal powder (A); an epoxy resin (B); a cationic curing agent (C); and a blocked carboxylic acid (D); wherein the blocked carboxylic acid (D) is a compound obtained by reacting a compound (d1) selected from carboxylic acids and carboxylic acid anhydrides with a vinyl ether compound (d2). | 2018-03-01 |
20180057633 | POLYMERIC COMPOSITES AND ARTICLES FORMED THEREOF - A downhole tool for controlling the flow of a fluid in a wellbore comprises: an annular body having a flow passage therethrough; a frustoconical element disposed about the annular body; a sealing element carried on the annular body and configured to engage a portion of the frustoconical element; and a bottom sub disposed about the annular body; wherein at least one of the frustoconical element and the bottom sub comprise a polymeric composite that includes: a polymer component comprising one or more of the following: a poly(ether ether ketone); or an epoxy, and a filler crosslinked with the polymer component. | 2018-03-01 |
20180057634 | METHODS OF MAKING POLYPEPTIDES - Various embodiments disclosed relate to a method of forming a polypeptide. The method includes contacting a first amino acid-derived N-thiocarboxyanhydrosulfide monomer as a crystalline solid with a polymerization initiator (e.g., in an alkane suspension) to give a polypeptide product. The method further includes contacting the polypeptide product with a second amino acid-derived N-thiocarboxyanhydrosulfide monomer in an alkane suspension. | 2018-03-01 |
20180057635 | POLYARYLENE SULFIDE RESIN, METHOD FOR PRODUCING SAME, POLY(ARYLENE SULFONIUM SALT), AND METHOD FOR PRODUCING POLY(ARYLENE SULFONIUM SALT) - Disclosed is a production method comprising a step of obtaining a poly(arylene sulfonium salt) comprising a terminal group including at least one functional group selected from the group consisting of a carboxy group, a hydroxy group and an amino group, and a step of dealkylating or dearylating the poly(arylene sulfonium salt) to obtain a polyarylene sulfide resin, and a polyarylene sulfide resin comprising a terminal group including a functional group obtainable by the production method. | 2018-03-01 |
20180057636 | AROMATIC POLYSULFONE - An aromatic polysulfone produced by polymerizing a dihalogeno compound represented by general formula (A) shown below, and a dihydric phenol represented by general formula (B) shown below, the aromatic polysulfone having a value (Mw/Mn) for the ratio between the weight average molecular weight (Mw) and the number average molecular weight (Mn) of less than 1.8, and having a number average molecular weight (Mn) of at least 6,000 but less than 14,000. | 2018-03-01 |
20180057637 | METHOD FOR PRODUCING A CROSS-LINKED SILOXANE NETWORK - A method for producing a cross-linked siloxane network comprises the steps of: (a) providing a first part comprising (i) a first siloxane compound comprising at least one cyclic siloxane moiety, (ii) an inorganic particulate material, and (iii) an aminosilane compound, (b) providing a second part, the second part comprising a hydroxide salt, (c) combining the first part and the second part to produce a reaction mixture, (d) heating the reaction mixture to a temperature sufficient for the hydroxide salt to open the ring of the cyclic siloxane moiety, and (e) maintaining the reaction mixture at an elevated temperature so that at least a portion of the opened cyclic siloxane moieties react to produce a cross-linked siloxane network. | 2018-03-01 |
20180057638 | SILICONE RESIN SUBSTRATE, METAL LAYER-FORMED SILICONE RESIN SUBSTRATE, CURED SILICONE RESIN SUBSTRATE, AND METAL LAYER-FORMED CURED-SILICONE RESIN SUBSTRATE - The present invention provides a silicone resin substrate, including quartz cloth and a silicone resin composition, wherein the silicone resin composition contains a silicon atom-bonded aryl group in an amount of 10% by mol or more and 99% by mol or less based on the whole silicon atom-bonded organic groups contained in the silicone resin composition. The present invention also provides a metal layer-formed silicone resin substrate, a cured silicone resin substrate, and a metal layer-formed cured-silicone resin substrate, using the silicone resin substrate. Each substrate excels in heat resistance and weather resistance as well as dielectric properties at high frequency. | 2018-03-01 |
20180057639 | METHOD FOR PRODUCING HEAT-SHIELDING FILM - A pore sealing treatment is performed in order to enhance the heat-shielding property of an anode oxide film by blocking at least the openings of open pores. In the first step of the pore sealing treatment, a solvent-typed pore sealing agent (first pore sealing agent) is used, and a first silicon-based oxide film is formed. In the second step of the pore sealing treatment, a non-solvent-typed pore sealing agent (second pore sealing agent) is used, and a second silicon-based oxide film is formed. In contrast to the first pore sealing agent, the second pore sealing agent is substantially free from the volume contraction in the application step or in the firing step. Consequently, even when the incompletely blocked openings remain after the first step, these incompletely blocked openings can be certainly blocked by the second silicon-based oxide film. | 2018-03-01 |
20180057640 | COATING COMPOSITIONS AND COATINGS FOR ADJUSTING FRICTION - An alkoxysilane functionalized polysiloxane polymer can be prepared from a mixture of reactants including: a) a polysiloxane polymer having two or more reactive functional groups selected from -A-NH2, -A-OH, -A-N═C═O, -A-COOH, | 2018-03-01 |
20180057641 | BOTH-TERMINAL MODIFIED POLYSILOXANE MACROMONOMER AND A METHOD FOR PREPARING THE SAME - One of the purposes of the present invention is to provide a polysiloxane macromonomer which has high hydrophilicity and a narrow molecular weight distribution and is usable as a material for ophthalmic lenses. The present invention provides a method for preparing a both-terminal modified polysiloxane macromonomer represented by the following average structural formula [I]: | 2018-03-01 |
20180057642 | ISOTACTIC POLYPROPYLENE BASED COMPOSITE - This invention relates to a process for producing an isotactic polypropylene based composite, comprising: reactive blending of isotactic polypropylene homo-polymer; polypropylene grafted with a carboxylic anhydride or a furan type moiety such as maleic anhydride grafted polypropylene; and an amino silane such as (3-aminopropyl)triethoxysilane to produce an isotactic polypropylene based composite such that the crystallization temperature of the isotactic polypropylene based composite is in a range of about 120° C. to about 126° C. The reactive blending can further take place in the presence of an organically modified nanoclay. | 2018-03-01 |
20180057643 | MASTERBATCH COMPRISING COLORANT PARTICLES AND A POLYOL POLY(HYDROXY FATTY ACID) ESTER AS DISPERSING AGENT - The present invention relates to a masterbatch comprising colorant particles, a polyol poly(hydroxy fatty acid) ester dispersing agent and a carrier resin. The masterbatch is used for coloring thermoplastic polymer compositions. The present invention also relates to a method for producing said masterbatch, a colored thermoplastic polymer composition comprising said masterbatch and colored thermoplastic products formed of said colored thermoplastic composition. | 2018-03-01 |
20180057644 | Polyolefin Pipe - This invention relates to a polymeric pipe, and more particularly a polymeric pipe where the pipe comprises a cross-linked polyolefin formed from extruded polyolefin comprising a bismaleimido crosslinker. This invention relates to the manufacturing of plastic pipes and tubing of polyolefinic polymers such as polyethylene, with crosslinking by a bismaleimido crosslinker, to produce crosslinked polyethylene (PEX) pipes and tubing. | 2018-03-01 |
20180057645 | TWO-COMPONENT TYPE EPOXY RESIN COMPOSITION FOR FIBER-REINFORCED COMPOSITE MATERIAL, AND FIBER-REINFORCED COMPOSITE MATERIAL - A two-component type epoxy resin composition for a fiber reinforced composite material is a two-component type epoxy resin composition for a fiber reinforced composite material that includes the following components [A] to [C], wherein the content of the component [C] is 6 to 25 mass parts relative to 100 mass parts of the component [A]. The fiber reinforced composite material is a fiber reinforced composite material made by combining and curing the two-component type epoxy resin composition for the fiber reinforced composite material and a reinforcing fiber, [A]: an epoxy resin, [B]: an acid anhydride and [C]: a quaternary ammonium salt or a quaternary phosphonium halide or an imidazolium salt. | 2018-03-01 |
20180057646 | CARBON FIBER COMPOSITE, A MEDIUM INCORPORATING THE CARBON FIBER COMPOSITE, AND A RELATED METHOD - Carbon fiber composite additives, media incorporating the carbon fiber composites, and related methods are provided herein. In some aspects, a composition includes at least one medium; and a carbon fiber composite incorporated with the at least one medium, the carbon fiber composite including one or more carbon fibers with an epoxy resin matrix applied thereto to produce a composition having improved characteristics and filtration performance. | 2018-03-01 |
20180057647 | Wrapping Tape With Depressions - A wrapping tape may be formed of a length of elastically deformable material with a length, uniform width along the length, a top side, and a bottom side. A first edge of the tape is parallel to a second edge, thereby defining the uniform width. The tape includes a first depression formed into the top side and alongside the entire first edge. A second depression is also formed into the bottom side and alongside the entire second edge. The first depression on the top side is configured to be received into the second depression on the bottom side when the wrapping tape is wrapped around a cylinder, thereby overlapping the tape upon itself as it is wrapped. The depressions prevent the formation of a protruding bulge as the tape is overlapped. | 2018-03-01 |
20180057648 | SILICONE RESIN TRANSPARENT SUBSTRATE AND METHOD FOR MANUFACTURING THE SAME - The present invention provides a silicone resin transparent substrate, including one or more than one prepreg containing a silicone resin composition and a fibrous base, wherein the silicone resin transparent substrate has: an attached amount of the silicone resin composition to the fibrous base of 60% by mass or more and 99% by mass or less; a total light transmittance of 80% or more at 450 nm, as measured by a method disclosed in JIS K 7375:2008 in a thickness of 0.1 mm to 0.4 mm; and a water vapor permeability of 65 g/m | 2018-03-01 |
20180057649 | OVERCOATED WATER-SOLUBLE FILMS - A multilayer film comprising: (a) a layer of a first polymer comprising polymerized units of vinyl alcohol; and (b) a layer of a second polymer selected from the group consisting of maleic anhydride-isobutylene copolymers, neutralized maleic anhydride-isobutylene copolymers, chemically modified maleic anhydride-isobutylene copolymers, ethylene-acrylic acid copolymer, neutralized ethylene-acrylic acid copolymer, polyvinylpyrrolidone, poly (vinyl methyl ether), cellulose, methyl cellulose, hydroxyethyl cellulose, poly(methyl)acrylic acid, poly(ethylene glycol), polyacrylamine, poly(2-hydroxyethyl acrylate), and mixtures thereof. | 2018-03-01 |
20180057650 | MOLDED POLYURETHANE BODIES WITH EXCELLENT FLEXIBILITY AT LOW TEMPERATURE - The present invention relates to a process for producing polyurethane moldings, wherein (a) organic polyisocyanates are mixed with (b) one or more compounds having at least two hydrogen atoms which are reactive toward isocyanate, comprising polyester polyol, (c) blowing agent, (d) catalyst, and (e) propylene carbonate and compounds selected from the group consisting of at least one compound of the general formula (I) and a compound of the formula (II), to give a reaction mixture, introduced into a mold and allowed to react to give a polyurethane molding. The present invention further relates to polyurethane moldings obtainable by such a process and also the use of these moldings as steering wheels, seats, armrests and in particular as shoe soles. | 2018-03-01 |
20180057651 | POLYPROPYLENE FOAMS AND PROCESSES OF MAKING - The present disclosure provides a linear polypropylene foam with, for example, low density and/or high expansion ratio, said linear polypropylene foam comprising at least one polypropylene, at least one alpha nucleating agent, and at least one beta nucleating agent. The present disclosure also provides compositions and processes for making said linear polypropylene foam. | 2018-03-01 |
20180057652 | SPONGE-FORMABLE SILICONE RUBBER COMPOSITION AND SILICONE RUBBER SPONGE - A sponge-formable silicone rubber composition of the present invention comprises (A) a polyorganosiloxane having at least two silicon-bonded alkenyl groups per molecule, (B) a polyorganosiloxane having at least two silicon-bonded hydrogen atoms per molecule, (C) water, (D) a thickening agent, (E) an emulsifier, (F) a halogen-containing ion conductor of an alkali metal, and (G) a hydrosilylation reaction catalyst. The sponge-formable silicone rubber composition can form a silicone rubber sponge having uniform and fine bubbles and having small distortion due to contraction after secondary vulcanization. | 2018-03-01 |
20180057653 | FIBRILLATED POLYMER COMPOSITIONS AND METHODS OF THEIR MANUFACTURE - The disclosure is directed to polymer compositions comprising a matrix polymer component comprising a crystalline or semi-crystalline polymer; and a fibrillated fluoropolymer, a fibrillated fluoropolymer encapsulated by an encapsulating polymer, or a combination thereof. Methods of preparing and using these polymer compositions, as well as articles comprising the polymer compositions, as also described. | 2018-03-01 |
20180057654 | PROCESS FOR PRODUCING POROUS MATERIALS - The present invention relates to a process for preparing a porous material, at least providing a mixture (I) comprising a composition (A) comprising components suitable to form an organic gel and a solvent (B), reacting the components in the composition (A) in the presence of the solvent (B) to form a gel, and drying of the gel obtained in step b), wherein the composition (A) comprises a catalyst system (CS) comprising a catalyst component (C1) selected from the group consisting of alkali metal and earth alkali metal, ammonium, ionic liquid salts of a saturated or unsaturated monocarboxylic acid and a carboxylic acid as catalyst component (C2). The invention further relates to the porous materials which can be obtained in this way and the use of the porous materials as thermal insulation material and in vacuum insulation panels, in particular in interior or exterior thermal insulation systems as well as in water tank or ice maker insulation systems. | 2018-03-01 |
20180057655 | TRANSPARENT RESIN COMPOSITION AND HEAT RAY-SHIELDING FILM - Provided is a transparent resin composition having a higher heat ray-shielding effect that can particularly effectively shield light of a wavelength of 1,450 nm to 1,750 nm while ensuring a high visible light transmittance. The transparent resin composition contains a transparent resin-forming component and inorganic particles, in which the inorganic particles contain indium tin oxide (ITO) and have a color having an L* value of 30 or more and 55 or less and a b* value of −18 or more and −10 or less in the Lab color space. | 2018-03-01 |
20180057656 | RADIOOPAQUE PEEK BASED BLOCK FOR USE IN A CAD/CAM SYSTEM FOR THE MANUFACTURE OF A DENTAL RESTAURATION - Block for use in a CAD/CAM system for the manufacture of a dental restauration, said block consisting of a thermoplastic polymer comprising PEEK including radiopaque particles selected from the group comprising BaZrO | 2018-03-01 |
20180057657 | Method and System for the Recycling and Reuse of Coal Ash - A method for the reuse of coal composition products and a resultant material are disclosed. The method generally utilizes the steps of heating a plastic component to a melting point, adding a predetermined quantity of coal combustion products to the melted plastic, mixing, and cooling the mixture to a solid state. Preferably the end product of the mixture is comprised of 75% recycled plastic and 25% coal combustion products. | 2018-03-01 |
20180057658 | QUANTUM DOT ARTICLE WITH THIOL-EPOXY MATRIX - Described is a quantum dot film article comprising a quantum dot of a cured thiol-epoxy matrix. The matrix formulations resist ingress from water and/or oxygen, while also providing acceptable color stability upon aging. | 2018-03-01 |
20180057659 | THERMALLY STABILIZED POLYARYLENE COMPOSITIONS - A polyarylene composition containing one or more polyarylenes and one or more sterically hindered phenolic stabilizers. The polyarylene composition has enhanced resistance to discoloration and degradation under thermal stress. | 2018-03-01 |